WuXi PharmaTech Buys XenoBiotic, a US-China CRO

WuXi PharmaTech has strengthened its laboratory testing capabilities by acquiring XenoBiotic Laboratories, a US-China pre-clinical CRO. XBL has specific expertise in radio-labeled compound studies. XBL provides bioanalytical, drug metabolism, and pharmacokinetic services from its New Jersey and Nanjing labs. As part of the acquisition, Dr. Jinn Wu, President and CEO of XBL, will become Vice President and Chief Scientific Officer of WuXi's Laboratory Testing Division. More details.... Stock Symbol: (NYSE: WX) Share this with colleagues: // //